lobbying_activities: 2031304

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
2031304	192b8d52-6451-42e3-b6b1-695a404e02e4	Q3	KOUNTOUPES DENHAM CARR & REID, LLC	320918	ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN)	2017	third_quarter	PHA	Policy matters related to generic pharmaceuticals and biosimilars, including reauthorization of the Generic Drug User Fee Agreement, reauthorization of the Biosimilar User Fee Agreement, H.R. 2051, The FAST Generic Act of 2017, S.771 and H.R. 1776, Improving Access to Affordable Drugs, and changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Issues related to drug takeback and opioid addition. Issues realted to H. R. 2212 and S. 974, CREATES Act of 2017.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE	60000		0	0	2017-10-18T17:38:30.503000-04:00